Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hemant K. Tewary"'
Autor:
Hemant K. Tewary, Patrick L. Iversen
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 15:1127-1135
Part I of this review has already been presented on methods of processing and purification of crude or raw samples in cell-culture or cell free systems. Part II of the review focuses on the in vivo models of determination of input oligonucleotides in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97da624a0a69bfc7450b8042294e5bbc
https://doi.org/10.1016/s0731-7085(97)01942-0
https://doi.org/10.1016/s0731-7085(97)01942-0
Publikováno v:
Toxicology Letters. :425-430
Phosphorothioate oligonucleotides (PS-ODN) designed to temporarily modulate selected gene expression have made the journey from bench top to beside in a remarkably short period of time. A PS-ODN with sequence complementary to the p53 mRNA was adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40bced0036c605d81e654d463e4916ae
https://doi.org/10.1016/0378-4274(95)03572-9
https://doi.org/10.1016/0378-4274(95)03572-9
Publikováno v:
Antisense Research and Development. 5:131-139
Phosphorothioate oligonucleotides (S-ODNs) have the ability to modulate gene expression selectively and thus have potential therapeutic capabilities. This potential led us to investigate the protein binding characteristics of selected S-ODNs. We eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef5568514355d0f67d7269b65c5abf9
https://doi.org/10.1089/ard.1995.5.131
https://doi.org/10.1089/ard.1995.5.131
Current therapy for acute myelogenous leukemia (AML) includes induction with Ara-C and an anthracycline, such as daunorubicin, idarubicin, or mitoxantrone. Unfortunately, most patients relapse from initial remission. Nearly one-fifth of early relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a4445930b9ff6d085e5db4b4f2f78db
https://doi.org/10.1385/0-89603-305-8:201
https://doi.org/10.1385/0-89603-305-8:201
Autor:
Gerald Zon, Anne Kessinger, J. Graham Sharp, Michael R. Bishop, Hemant K. Tewary, Mark A. Arneson, Patrick L. Iversen, Raymond W. Ruddon, James O. Armitage, E. Bayever, Samuel J. Pirruccello
Publikováno v:
Antisense research and development. 3(4)
A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4dd9bf1988a10e50c2d956a2d21254
https://pubmed.ncbi.nlm.nih.gov/8155979
https://pubmed.ncbi.nlm.nih.gov/8155979